Status:
TERMINATED
Serp-1 for the Treatment of Acute Coronary Syndrome
Lead Sponsor:
Viron Therapeutics Inc
Conditions:
Unstable Angina
Coronary Atherosclerosis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Males and females aged 18-80 years who present with ACS (unstable angina and non ST-elevation MI) defined as one or more episodes of angina lasting at least 5 minutes in the last 24 hours before admis...
Detailed Description
A total of 72 subjects will be enrolled, separated into 3 dose groups and centrally randomized in a 3:1 ratio of Serp-1 injection to placebo control.Subjects will receive Serp-1 by intravenous (IV) bo...
Eligibility Criteria
Inclusion
- Established diagnosis of unstable angina or NSTEMI with one or more episodes of angina in the 24 hours before hospital admission
- Scheduled for PCI
Exclusion
- CABG within 6 months
- Acute ST elevation, eligible for thrombolysis on initial examination
- Coronary lesions with total thrombotic occlusions
- Current immunosuppressant therapy
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00243308
Start Date
October 1 2005
End Date
December 1 2008
Last Update
February 6 2009
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington Hospital Center
Washington D.C., District of Columbia, United States, 20010
2
University of Florida
Gainesville, Florida, United States, 32610-0277
3
Spectrum Health
Grand Rapids, Michigan, United States, 49525
4
Victoria Heart Institute
Vicotria, British Columbia, Canada, V8R 4R2